-   Training & Support

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised biological agents for
patients with Crohn's disease (CD) and fistulising Crohn's disease
(FCD).

CD and listing dates

CD is an immune condition affecting the gastrointestinal tract.

Listing dates:

-   infliximab - 1 October 2007
-    adalimumab - 1 August 2008
-    vedolizumab - 1 August 2015
-    ustekinumab - 1 September 2017

See Written Authority Required Drugs for more information.

FCD and listing dates

FCD is a similar condition to CD affecting the gastrointestinal tract.

Listing dates:

-   infliximab - 1 August 2010
-    adalimumab - 1 April 2011

See Written Authority Required Drugs for more information.

Treatment specifics

A break in treatment cycles is measured:

-   from the date of last approval for PBS-subsidised biological
    medicine treatment in the most recent cycle
-    to the date of the first application for initial treatment with a
    biological medicine under the new treatment cycle

There is no limit to the number of treatment cycles.

See Treatment breaks and failures for full details.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, calculation
sheets, contact details, item and restriction codes, treatment
specifics, FAQs, the PBS schedule and the Services Australia website.

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing written authority approval requests

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
